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Introduction: Zymogen granule glycoprotein 2 (GP2) was demonstrated as first
autoimmune mucosal target in primary sclerosing cholangitis (PSC) associated with
disease severity. Autoantibodies to four GP2 isoforms (aGP21−4) were found in patients
with inflammatory bowel diseases but reactivity against specific GP2 epitopes has not
been investigated in PSC yet. Hence, the prevalence of aGP21−4 and their association
with the PSC phenotype for risk prediction were examined.
Methods: GP2 isoforms were stably expressed as glycosylphosphatidyl -
inositol-anchored molecules in the membrane of HEp-2 cells and used as autoantigenic
targets in indirect immunofluorescence assay (IFA). aGP21−4 IgA and IgG were detected
by IFA in 212 PSC patients of four European university hospitals and 145 controls
comprising 95 patients with cystic fibrosis and 50 healthy subjects.
Results: Combined aGP21 and aGP24 IgA testing with a sensitivity of 66.0%
and a specificity of 97.9% resulted in the best diagnostic performance (Youden
index: 0.64) regarding all aGP2 and combinations thereof. aGP24 IgA positivity is
significantly associated with the presence of cirrhosis in PSC (p = 0.0056). Logistic
regression revealed the occurrence of aGP21 IgA (odds ratio [OR] 1.38, 95%
confidence interval [CI]: 1.03–1.86) and aGP24 IgA (OR 1.52, 95%CI: 1.07–2.15) along
with male gender (OR 0.51, 95%CI: 0.27–0.97) and older age (OR 1.03 95%CI:
1.01–1.05) as significant risks for the concomitant presence of cirrhosis in PSC.
Sowa et al. IgA to GP2 Isoforms in PSC
Conclusions: Combined aGP21 and aGP24 IgA analysis is preferred to single aGP2
isoform analysis for sensitive PSC autoantibody testing. Positivity for aGP21 and aGP24
IgA is associated with cirrhosis in PSC and could be used for risk stratification.
Keywords: zymogen granule glycoprotein 2, primary sclerosing cholangitis, cirrhosis, cholangiocarcinoma,
immunoglobulin A
INTRODUCTION
Primary sclerosing cholangitis (PSC), a chronic immune-
mediated, life threatening, genetically predisposed, cholestatic
liver illness, is associated with the co-occurrence of inflammatory
bowel disease (IBD) and in particular with the phenotype thereof
(1, 2). The prevalence of PSC is estimated at up to 16.2 per
100,000 individuals and still rising (3, 4). There is a clinical
need for markers predicting PSC severity and prognosis despite
recent progress regarding the use of certain serum and bile
proteins (5, 6). Further, IgA to zymogen granule glycoprotein
2 (GP2) was identified as a novel marker candidate for disease
severity and cholangiocarcinoma in PSC (7, 8). Glycoprotein 2 is
a microbe-sensing (9, 10) and immunomodulating molecule (11)
with two major sources (pancreas and intestine) (12). Of note,
GP2 was originally identified as a target of Crohn’s disease (CD)-
specific pancreatic antibodies (13, 14). Upon specific binding to
FimH, GP2 interacts selectively with bacterial species including
pathogens (10) and, thus, may determine both innate and
acquired immune responses to the intestinal microbiota (11, 15).
There is mounting evidence that mucosal interactions between
the intestinal microbiota and host immune responses partake
in the development of chronic inflammatory disorder of the
gastrointestinal tract (12, 16–18).
Since the first report of GP2’s over-expression in the
inflamed intestine of CD patients (13), several cross-sectional
and prospective studies demonstrated the association of
autoantibodies (autoAbs) to GP2 (aGP2) with the stricturing
and/or stenosing CD phenotype and disease severity (18, 19),
earlier surgical recurrence after first surgery (20), as well as de-
novo development of CD in patients with suspected ulcerative
colitis (UC) after ileal pouch surgery and development of
subsequent pouchitis (21). Thus, autoimmunity to GP2 appears
to be a stratification factor of the clinical phenotype in IBD (18).
Given the close association of PSC with IBD, the occurrence
of aGP2 IgA in severe PSC (7) provided further evidence for
the correlation of the mucosal loss of tolerance to GP2 with
fibrostenotic changes as reported in IBD (22). Remarkably, a
recent comprehensive retrospective outcome analysis of 7,121
PSC patients at 37 centers in Europe, North America, and
Australia revealed that 70% of them developed IBD at some point
(1). Conversely, PSC appeared to be underestimated around
Abbreviations:GP2, zymogen glycoprotein 2; PSC, primary sclerosing cholangitis;
GP21, GP2 isoform 1; IFA, indirect immunofluorescence assay; OR, odds ratio; CI,
confidence interval; IBD, inflammatory bowel disease; CD, Crohn’s disease; UC,
ulcerative colitis; autoAb, autoantibody; ELISA, enzyme-linked immunosorbent
assay; GPI, glycosylphosphatidylinositol; AIH, autoimmune hepatitis; CF, cystic
fibrosis; HS, healthy subjects; IQR, interquartile range; LTx, liver transplantation;
YI, Youden index
three-fold in long-term IBD and to progress in subclinical IBD
patients (23).
In total, four human GP2 isoforms (GP21−4) were identified
(18, 24) and respective autoAbs detected in patients with
IBD which demonstrated differing test performances by
enzyme-linked immunosorbent assay (ELISA) (20, 25, 26).
Hence, stable HEp-2 cell-lines expressing GP2 isoforms
as glycosylphosphatidylinositol (GPI)-anchored membrane
molecules and one cell line with an empty vector as control
were generated to elucidate the role of loss of tolerance to
GP2 isoforms in PSC. Consequently, IgG and IgA aGP21−4 by
indirect immunofluorescence assay (IFA) in patients with PSC
and controls were determined.
METHODS
Patients
Patients with PSC were recruited from four European university
hospitals specialized in autoimmune liver diseases (Table 1).
All PSC patients were examined clinically and endoscopically
for concomitant IBD and autoimmune hepatitis (AIH). The
diagnosis of PSC and IBD was based on clinical, radiologic,
endoscopic, and histologic evaluation (27–29).
In total, 145 gender-matched controls were enrolled in this
study comprising 95 patients with cystic fibrosis (CF) and 50
healthy subjects (HS). The patients with CF, a multi-systemic
disorder with exocrine pancreatic insufficiency and biliary
cirrhosis with a different pathogenesis, were included as disease
controls with regard to PSC. The 50 apparently healthy subjects
(HS) with no liver or intestinal pathology were both age- and
gender-matched.
The study was approved by the ethics committees of the
participating centers. Written informed consent was obtained
from all patients included in this study. The study was conducted
in accordance with the principles of the Declaration of Helsinki
(World Medical Association Declaration of Helsinki 1989).
Generation of GP2-Expressing Cell Lines
Stable HEp-2 cell lines expressing membrane GPI-anchored GP2
isoforms were generated through transduction with lentiviruses.
Briefly, coding sequences of GP2 isoforms sequences were
amplified with PCR and cloned into pLVX-IRES-puro plasmids
each using T4 DNA ligase (ThermoFisher Scientific, Waltham,
USA) in accordance with the manufacturer’s protocol. To
confirm successful cloning, plasmids were Sanger sequenced.
For transduction, lentiviruses were produced using the Lenti-X
Lentiviral Expression System (Clontech Laboratories, Mountain
View, USA). Thus, an 80% confluent Lenti-X 293T cell line
was co-transfected with the six plasmids containing GP2
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TABLE 1 | Demographic and clinical data of patients and controls.
n Age
(IQR)
f
(%)
IBD
(%)
CD
(%)
UC
(%)
AIH
(%)
Cirrhosis
(%)
CCa
(%)
LTx
(%)
PSC 212 43.0
(23.3)
70
(33.0)
136
(64.2)
17
(8.0)
119
(56.1)
20
(9.4)
86
(31.6)
5*
(3.7)
81
(38.2)
Berlin 23 52.5
(17.5)
6
(26.1)
19
(82.6)§3
2
(8.7)
17
(73.9)
1
(4.3)
19
(82.6)
0 19
(82.6)
Hamburg 30 50.0
(17.3)
18
(60.0)§2
15
(50.0)
4
(13.3)
11
(36.7)§5
5
(16.7)
3
(10.0)§6
0 0
London 83 46.3
(18.7)
23
(27.7)
53
(63.9)
1
(1.2)§4
52
(62.7)
5
(6.0)
49
(59.0)§8
5
(6.0)
57
(68.8)
Debrecen 76 34.1
(21.6)§1
23
(30.3)
49
(64.5)
10
(13.2)
39
(51.3)
9
(11.8)
15
(19.7)§7
0 6
(7.9)§9
Controls 145 26.9
(22.1)&
63
(43.4)
0$ 0$ 0$ 0$ 0$ 0 0
CF 95 15.6
(20.9)&
44
(46.3)$
0$ 0$ 0$ 0$ 0$ 0 0
HS 50 36.0
(18.0)
19
(38.0)
0$ 0$ 0$ 0$ 0$ 0 0
AIH, autoimmune hepatitis; CCa, cholangiocarcinoma; CD, Crohn’s disease; CF, cystic fibrosis; f, females; HS, healthy subjects; IQR, interquartile range; LTx, liver transplantation; n,
number; PSC, primary sclerosing cholangitis; UC ulcerative colitis. *Related to 136 patients with PSC.
Comparison of the prevalence in all patients with primary sclerosing cholangitis with control groups: &p < 0.05 by Kruskal-Wallis test for continuous variables.
Comparison of the prevalence in all patients with primary sclerosing cholangitis with control groups: $p < 0.05 by Fisher’s exact test for dichotomous values.
Comparison of the prevalence within the cohorts of patients with primary sclerosing cholangitis:
§1 Debrecen vs. Berlin, Hamburg and London, respectively (p < 0.05 by Kruskal–Wallis test).
§2 Hamburg vs. Berlin, Debrecen and London, respectively (p < 0.05 by Fisher’s exact test).
§3 Berlin vs. Hamburg (p < 0.05 by Fisher’s exact test).
§4 London vs. Hamburg and Debrecen, respectively (p < 0.05 by Fisher’s exact test).
§5 Berlin vs. Hamburg and London, respectively (p < 0.05 by Fisher’s exact test).
§6 Hamburg vs. Berlin and London, respectively (p < 0.05 by Fisher’s exact test).
§7 Debrecen vs. Berlin and London, respectively (p < 0.05 by Fisher’s exact test).
§8 London vs. Berlin (p < 0.05 by Fisher’s exact test).
§9 Debrecen vs. Berlin and London, respectively (p < 0.05 by Fisher’s exact test).
isoforms or an “empty” vector. The harvested supernatants
were concentrated by centrifugation in Amicon Ultra-15
centrifugal filter units (Merck Millipore, Darmstadt, Germany)
and employed for transduction of HEp-2 cells. Selection of
successfully transduced cells was performed by adding the
antibiotic puromycin to cell culture.
Confirmation of GP2 transduction into HEp-2 cells was
done with reverse transcription quantitative polymerase chain
reaction (RT qPCR). In brief, RNA from transduced cells was
isolated with RNeasy Mini Kit according to the manufacturer’s
protocol (Qiagen, Hilden, Germany). After RT reaction using
Maxima First Strand Synthesis Kit (ThermoFisher Scientific),
qPCR was performed in the CFX96 Touch Real-Time PCR
Detection System (Bio-Rad Laboratories, München, Germany)
with following primers: 5- ATCAACGTGATTCCACCATCC-
3 and 5- TTGAGCAAGAAGGCTGGC-3 (for GP2
gene); 5-AAATGTTTCATTGTGGGAGC-3 and 5-
ATATGAGGCAGCAGTTTCTC-3 (for RPLP0 gene). RPLP0
was used as reference gene. Obtained PCR products were
analyzed by electrophoresis.
Expression of GP2 isoform proteins was confirmed by
Western blotting. Briefly, transduced HEp-2 cells were lysed and
the lysate run on SDS-PAGE. Separated bands transferred on
the blotting membrane were developed with a rabbit polyclonal
antibody to GP2 reactive with all isoforms (GA Generic Assays,
Dahlewitz, Germany). Isoforms of GP2 were revealed by a
secondary anti-rabbit antibody conjugated with horse radish
peroxidase employing enhanced chemiluminescence.
Membrane expression of GPI-anchored GP2 isoforms was
confirmed by flow cytometry analysis.
Detection of IgG and IgA to GP2 Isoforms
IgG and IgA to GP2 isoforms were determined by IFA employing
stably transduced HEp-2 cells expressing membrane GPI-
anchoredGP2 isoforms 1-4. Briefly, cells were fixed on glass slides
as described elsewhere (30) and incubated with 1 in 20 diluted
sera for 1 h at room temperature. HEp-2 cells transduced with
an empty vector were used as negative control. After washing,
bound autoAbs to GP2 isoforms were revealed by incubation
of polyclonal anti-human IgG or IgA antibodies conjugated to
fluorescein isothiocyanate (FITC) (Agilent, Santa Clar, USA) for
1 h at room temperature. A fluorescent microscope (Axiovert 40,
Zeiss, Göttingen, Germany) was used to read specific staining
of HEp-2 cells. Brighter fluorescent staining of the cellular
membrane of transduced HEp-2 cells in comparison with HEp-2
cells transduced with an empty vector was scored positive.
Statistical Methods
Data were tested for normality by the Kolmogorov-Smirnov-
test and non-normally distributed data were reported by
median and quartile ranges. The two-tailed, Mann-Whitney
and Kruskal–Wallis tests were used to test for statistically
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FIGURE 1 | Detection of the membrane expression of GP2 isoforms in HEp-2 cells by flow cytometry. GP2 expressed in HEp-2 cells was stained with polyclonal
antibodies raised against full length human GP2 followed by FITC-conjugated anti-rabbit IgG: (A) HEp-2 cells expressing human GP2 isoform 1; (B) GP2 isoform 2;
(C) GP2 isoform 3; (D) GP2 isoform 4; (E) HEp-2 cells transduced with an empty vector; black solid lines: primary and secondary antibody staining; black dotted
lines: secondary antibody staining only.
significant differences of independent samples in 2 and more
groups, respectively. Prevalence comparison between groups was
performed by two-tailed Fisher’s exact test. Logistic regression
analysis was employed to test for the influence of explanatory
(independent) variables on a binomial response variable and to
detect possible clinical confounders on such association (age,
gender, concomitant IBD, concomitant overlap with AIH) by a
backward exclusion strategy resulting in adjusted odds ratios.
P < 0.05 was considered as significant. MedCalc software
version 12.7.0.0 (MedCalc, Mariakerke, Belgium) was used for
performing statistical analysis.
RESULTS
Detection of Autoantibodies to GP2
Isoforms by Indirect Immunofluorescence
GP2 isoforms were expressed stably in HEp-2 cells as GPI-
anchoredmolecules in themembrane of these cells by lentiviruses
transduction. As control, one cell line was transduced with an
empty vector only. The presence of membrane-bound GP21 to
GP24 in the respective lines and their absence in the empty vector
cell line was confirmed by FACS analysis (Figure 1).
For the detection of aGP21 to aGP24 by IFA, cells of each line
were fixed to conventional glass slides and used as targets for
specific autoAb analysis (Figure 2).
Occurrence of IgA and IgG to GP2
Isoforms in Patients and Controls
IgA and IgG against GP21−4 were determined in 212 patients
with PSC of four European hospitals and 145 gender-matched
controls. Of note, the 50 HS included as controls were gender- as
well as aged-matched to all PSC patients (Table 1). Patients with
PSC of the Debrecen cohort were significantly younger compared
to the remaining three PSC cohorts whereas the Hamburg cohort
had a significantly higher median age (p < 0.05, respectively).
Apart from aGP23, all other aGP2 demonstrated significantly
elevated prevalences in PSC patients compared with controls
including HS and patients with CF (p < 0.05, respectively)
(Table 2). However, this did not hold true for all PSC cohorts of
the four different centers.
Regarding IgA reactivity, aGP21 (47.2%) and aGP24 positivity
(48.6%) revealed the highest frequencies in PSC patients resulting
in an even significantly elevated combined positive rate of 66.0%
(aGP21and/or4 IgA) compared with both rates of single aGP2
isoform IgA testing (p< 0.0001,= 0.0004, respectively). Analysis
of all four aGP2 isoform IgA did not increase the positive rate
further. Apart from aGP23 IgA, all other aGP2 isoform IgA
demonstrated significantly lower prevalences in controls. Thus,
aGP21and/or4 IgA testing revealed the best Youden index (YI) of
0.64 being a measure of assay performance.
In terms of IgG, aGP21, and aGP24 testing revealed the highest
positive rates in PSC patients, too. However, their prevalences
were lower in contrast to the corresponding IgA, but only the
difference for aGP24 reached significance (p = 0.0395). Further,
both aGP2 isoform IgG had significantly more positives in the
control groups (p < 0.5, respectively). That resulted in halved
YIs for both and, thus, demonstrated a poorer assay performance
for the discrimination of patients with PSC from controls in
comparison to corresponding IgA analysis.
Association of IgA and IgG to GP2
Isoforms With PSC Phenotypes
The possible association of the presence of IgA and IgG to
GP21−4 in PSC patients with performed liver transplantation
(LTx) and concomitant occurrence of autoimmune hepatitis,
cirrhosis; cholangiocarcinoma, CD, UC, IBD (CD or UC) was
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FIGURE 2 | Indirect immunofluorescence assay for the detection of IgA to GP2 isoforms: Exemplarily, two patient sera and one serum of a healthy subject as control
were run on HEp-2 cells transduced with GP2 isoforms 1 (GP21) to 4 (GP24) with glycosylphosphatidylinositol anchor and an empty vector, respectively. Patient 1
demonstrated a strong specific binding to membrane-bound GP21 and a weak one to GP22, whereas patient 2 showed the typical binding pattern for a strong
positive binding to GP24 and a weak one for GP23. The healthy subject did not reveal a positive membrane-reactive pattern on the respective transduced HEp-2 cells.
investigated by Fisher’s exact test (Table 3). Further, established
associations were investigated by logistic regression analysis to
analyze the influence of confounding factors.
Association of IgA and IgG to GP2 Isoforms With
Cirrhosis
A significantly positive association of aGP2 isoform IgA and IgG
positivity in PSC was established for the concomitant occurrence
of cirrhosis. Thus, aGP21 and aGP24 IgA as well as aGP22 and
aGP24 IgG were more prevalent in PSC patients with cirrhosis
than in those without (p < 0.05, respectively). Similar positive
associations could be found in the larger cohorts from London
and Debrecen, too. Logistic regression analysis for the risk
analysis of the occurrence of cirrhosis in all 212 PSC patients
confirmed aGP21 and aGP24 IgA as independent predictors in
older male PSC patients (Table 4).
Association of aGP22 IgG With PSC Patients Without
LTx
A significantly negative association of aGP22 IgAwas revealed for
LTx performed in PSC patients of all cohorts. This significantly
more prevalent aGP22 IgA occurrence in PSC patients without
LTx was not detected in the single PSC cohorts but confirmed
by logistic regression analysis as independent predictor in PCS
patients without LTx demonstrating concomitant cirrhosis, UC
and no AIH overlap (Table 4).
Association of IgA and IgG to GP2 Isoforms With IBD
Patients with PSC and concomitant CD demonstrated a
significantly lower prevalence of aGP21/4 and aGP21/2/3/4 IgA.
However, this association was neither found in the single
PSC cohorts nor confirmed by logistic regression analysis.
There was no further association of all PSC patients with and
without IBD, UC or CD regarding the concomitant presence of
aGP2 isoform autoAbs by Fisher’s exact test. Only the London
cohort demonstrated significantly less frequent aGP23 IgG in
PSC patients with concomitant IBD and the Hamburg cohort
significantly less frequent aGP22 IgA in patients with UC (p <
0.05, respectively) (Table 3).
Logistic regression analysis revealed the concomitant
occurrence of UC as an independent risk factor for liver
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TABLE 3 | Positive and negative (italic) significant associations of IgA and IgG against GP2 isoforms 1 (aGP21) to 4 (aGP24) with the clinical phenotype in 212 patients
with primary sclerosing cholangitis (PSC) by Fisher’s exact test.
N IBD CD UC AIH Cirrhosis CCa LTx
PSC 212 aGP21/4 IgA
p = 0.01386
aGP21/2/3/4 IgA
p = 0.0076
aGP24 IgA
p = 0.0051
aGP21/4 IgA
p = 0.0056
aGP22 IgG
p = 0.0199
aGP24 IgG
p = 0.0447
aGP23 IgG
p < 0.0001
aGP22 IgA
p = 0.0006
Berlin 23
Hamburg 30 aGP22 IgA
p = 0.0472
London 83 aGP23 IgG
p = 0.0288
aGP24 IgA
p = 0.0055
aGP21/2/3/4 IgA
p = 0.0144
aGP23 IgG
p = 0.0316
Debrecen 76 aGP22 IgA
p = 0.0261
aGP22 IgG
p = 0.0349
AIH, autoimmune hepatitis; CCa, cholangiocarcinoma; CD, Crohn’s disease; LTx, liver transplantation; n, number; PSC, primary sclerosing cholangitis; UC ulcerative colitis.
TABLE 4 | Logistic regression analysis of independent variables for the risk prediction of liver transplantation (LTx) and the occurrence of cirrhosis in 212 patients with
primary sclerosing cholangitis (PSC).
Dependent variable Independent variable Coefficient SE OR 95% CI P
cirrhosis aGP21 IgA 0.3243 0.1514 1.3831 1.0279–1.8609 0.0322
aGP24 IgA 0.1729 0.1771 1.5178 1.0727–2.1478 0.0185
age 0.0273 0.0100 1.0277 1.0077–1.0480 0.0063
gender −0.6693 0.3235 0.5121 0.2716–0.9654 0.0385
LTx aGP22 IgA −3.02104 1.27092 0.0488 0.0040–0.5886 0.0175
cirrhosis 3.70772 0.49727 40.7608 15.3800–108.0262 <0.0001
AIH overlap −2.63423 1.00286 0.0718 0.0101–0.5124 0.0086
UC 1.82313 0.49012 6.1912 2.3691–16.1799 0.0002
The presence of IgA and IgG to GP2 isoforms 1 (aGP21 ) to 4 (aGP24 ) and the concomitant occurrence of inflammatory bowel disease, Crohn’s disease, ulcerative colitis (UC), and
autoimmune hepatitis overlap as well as age and gender were used as possible predictive independent variables for the logistic regression analysis.
CI, confidence interval, OR, adjusted odds ratio; SE, standard error.
transplantation along with cirrhosis. The presence of GP22
IgA and AIH overlap were negative predictors in this regard
(Table 4).
DISCUSSION
The recent reports of the occurrence of aGP2 IgA in patients
with large biliary duct disorders including PSC and of aGP2
IgA as marker of severe disease, as well as cholangiocarcinoma
ushered in a new era in PSC serology (7, 31). Until recently,
perinuclear antineutrophil cytoplasmic antibodies (ANCA) have
been considered as main serological marker of PSC (32) and
particularly ANCA IgA has been associated with cirrhosis linked
to intestinal infections (33). However, attempts to identify
the respective autoantigenic ANCA as well as other PSC-
specific targets have been inconclusive so far (34). Conversely,
IgG to proteinase 3 (PR3) being a cytoplasmic ANCA target
could be detected by highly sensitive enzyme immunoassays or
microbead-based immunoassays in up to 44% of patients with
PSC (35, 36). Thus, apart from the neutrophilic target PR3, GP2
was identified as an autoantigenic target in PSC and questions
on a possible pathogenic role of respective specific IgA being the
mucosal immunoglobulin in contrast to IgG were raised. Since
four GP2 isoforms were discovered and specific IgG and IgA
against them were described in patients with IBD (24–26, 37),
this study attempted to ascertain the frequency of IgG and IgA
to GP2 isoforms in PSC and their possible relation to the PSC
phenotype as stratification factor in PSC.
In contrast to recent reports demonstrating preferentially
aGP2 IgA in PSC (7, 8), this study revealed both IgA as well as
IgG against GP2 isoforms.
The IgG to GP2 isoforms determined in this study
demonstrated both lower sensitivities and specificities in contrast
to IgA against the corresponding GP2 isoforms which resulted
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in poorer assay performances of the former. Of note, apart from
significantly higher positive rates of IgG to GP2 isoforms in PSC,
we detected a significantly elevated prevalence of IgG GP23Ab
in control patients with CF (18.9%) vs. healthy controls (4.0%).
This finding warrants further investigation and could indicate a
different loss of tolerance to GP2 isoforms in CF.
In terms of discrimination of PSC from controls, aGP21 IgA
(47.2%) and aGP24 IgA-positives (48.6%) revealed the highest
frequencies amongst all aGP2. Interestingly, combination of
both led to a significantly elevated sensitivity of 66.0%. This
was a significantly higher prevalence than the corresponding
total prevalence reported by Jendrek et al. (66.0 vs. 48.7%, p <
0.0001). Thus, combined testing of both aGP21 and aGP24 IgA
appears more sensitive than the determination of IgA to just one
GP2 isoform. Indeed, the single positivity rates of aGP21 and
aGP24 IgA in this study were not significantly different from the
rate reported elsewhere. Further, due to the higher specificity,
combined aGP21 and GP24 IgA testing demonstrated the best
diagnostic performance for PSC by a YI of 0.64 regarding the
analysis of all aGP2 and combinations thereof.
As GP21 and GP24 represent long (537 amino acids) and
short GP2 isoforms (387 amino acids), respectively, they could
bear differing epitopes (24). Remarkably, GP22 and GP23 which
differ from GP21 and GP24 in just three amino acids (valine-
proline-arginine), respectively (25), demonstrated significantly
diminished IgA binding in PSC. This adds support to the notion
that GP2 isoforms bear different autoantigenic epitopes, all of
which should be contained in GP2-antigenic preparations in
aGP2 immunoassays for proper and accurate autoAb testing.
IgG and in particular IgA against GP2 isoforms revealed
different associations with the PSC phenotype. In fact, aGP21
and aGP24 IgA were demonstrated as positive predictors of
cirrhosis in older males with PSC. The cirrhosis in PSC is mainly
characterized by extensive fibrosis around the larger bile ducts
(4). An association of aGP2 IgG and IgA detected by ELISA with
the stenosing/stricturing phenotype in patients with CD, which is
characterized by fibrostenotic changes either, was established in
one longitudinal and several cross-sectional studies (18). Further,
the need for surgical resection and repeated surgical intervention
in CD was associated with the occurrence of aGP2 (20, 22).
Wölfel et al. demonstrated a significant association of aGP21 IgA
and a tendency for′ GP24 IgA with earlier surgical recurrence
in CD (20). Further, aGP21 and aGP22 IgA were reported to
be significantly associated with the stenosing/stricturing and
severity of disease but not with disease activity. Thus, IgA against
GP2 isoforms might be a serological marker for the development
of fibrostenotic changes in both the gut and larger bile ducts.
There is clearly a need for risk stratification in PSC (5, 38)
and aGP2 IgA could be of prognostic value like autoAbs to
gp210 do in primary biliary cholangitis (39). Given a potential
ascending pathophysiology of PSC, aGP21/4 IgA could be a
stage-defining biomarker (40). This is of interest, as aGP2 IgA
secreted onto mucosal surfaces might mediate the up-take of
GP2-covered bacteria by GP2-bearing M cells of the intestinal
follicle-associated epithelium (15, 41) and, thus, partake in
the development of severe complications or even pre-tumor
stages. Patients with PSC appear to demonstrate a gut microbial
signature distinct from both normal individuals and patients with
UC without liver disease whereas their microbial signature is not
dependent on the occurrence of IBD (42). Thus, fecal microbiota
profiles can be used as markers of PSC (43). Altogether, that hints
at an involvement of the microbiota in the pathophysiology of
PSC which was demonstrated in a well-establishedmouse models
for PSC and spontaneous bile duct inflammation (44, 45).
Interestingly, CD appears to confer prognostic favor in PSC
and a lower risk to develop adverse effects (1). Thus, it remains to
be determined in prospective studies whether aGP2-positive CD
patients characterized by complicated CD with fibrotic adverse
effects also demonstrate severe PSC.
All 5 PSC patients with cholangiocarcinoma demonstrated
aGP21 and/or aGP24 IgA. This might be a hint that aGP2 IgA
occurs earlier in the disease course and that the tolerance break
is linked with the mucosal microbiota interaction of GP2. In
this context, the elevation of aGP23 IgG in patients with CF is
of interest since approximately 30% of patients with CF have
clinically significant liver disease (46).
The finding that aGP21/4 and aGP21/2/3/4 IgA demonstrated
significantly lower prevalences in PSC patients with CD was
surprising.We speculate that PSCwith concomitant CDmight be
different from CD without obvious liver involvement regarding
the loss of tolerance to GP2. However, this notion needs to be
treated with caution since it could be confirmed neither in the
single cohorts nor by logistic regression analysis.
As most multi-center studies of this kind, our study lacks
perfection. The controls were not age matched to patients with
PSC due to the younger age of the controls with CF. Further, there
was a high level of diversity in the distinct PSC cohorts of the
four European hospitals regarding number of patients and their
phenotype. The established independent predictors of cirrhosis
aGP21 and aGP24 IgA could not be associated in all single cohorts
with the concomitant occurrence of cirrhosis.
Altogether, combined aGP21 and aGP24 analysis is required
for sensitive PSC-specific autoAb testing and should be preferred
to the autoAb analysis against single aGP2 isoforms only.
aGP21 and aGP24 IgA might be predictors of cirrhosis in PSC
and, thus, an useful alternative for risk prediction. Elevated
aGP2 IgA may demonstrate a link to fibrotic changes observed
in IBD in particular in CD. Prospective studies including
patients tested pre- and post-liver transplantation will provide
excellent hints regarding the pathophysiological role of these
autoAbs.
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